← Eichor
Condition: Hrd Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hrd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian
Phase 1 · 2 location(s) · University of Colorado, Denver · NCT06856499Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1 · 1 location(s) · Varun Monga, MBBS · NCT06177171Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase 3 · 59 location(s) · GOG Foundation · NCT05659381Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942HRD Tests for Ovarian cancER
Phase 2 · 4 location(s) · Centre Francois Baclesse · NCT06152731Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Phase N/A · 1 location(s) · Nordic Society of Gynaecological Oncology - Clinical Trials · NCT05574673Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-
Phase 2 · 2 location(s) · Jiangsu Cancer Institute & Hospital · NCT07311577PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
Phase 2 · 1 location(s) · Samsung Medical Center · NCT04819243An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therap
Phase 2 · 1 location(s) · Bai-Rong Xia · NCT07667751Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07033819Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovari
Phase 3 · 2 location(s) · Tongji Hospital · NCT06954584Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Phase 1 · 8 location(s) · Senhwa Biosciences, Inc. · NCT04890613Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05466786Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06141265Olaparib in Patients With HRD Malignant Mesothelioma
Phase 2 · 1 location(s) · University of Chicago · NCT04515836Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/Phase 2 · 5 location(s) · Maastricht University Medical Center · NCT04954599A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Phase 3 · 135 location(s) · Merck Sharp & Dohme LLC · NCT07318558Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's
NA · 1 location(s) · University of Saskatchewan · NCT06751303Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Inv
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06255392Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06622798PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Dam
Phase 2 · 6 location(s) · Institute of Cancer Research, United Kingdom · NCT03740893Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Phase 1/Phase 2 · 4 location(s) · AtlasMedx, Incorporated · NCT04503265
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.